The Journal of Pediatrics
Volume 152, Issue 4 , Pages 582-584 , April 2008

Decreased Bone Mineral Density with Off-Label Use of Tenofovir in Children and Adolescents Infected with Human Immunodeficiency Virus

An abstract of this study was presented at the 14th Conference on Retroviruses and Opportunistic Infections, February 25-28, 2007, in Los Angeles, California.

  • Julia B. Purdy, RN, MSN

      Affiliations

    • HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
    • ,
  • Rachel I. Gafni, MD

      Affiliations

    • HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
    • Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD
    • ,
  • James C. Reynolds, MD

      Affiliations

    • Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD
    • ,
  • Steven Zeichner, MD, PhD

      Affiliations

    • HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
    • ,
  • Rohan Hazra, MD

      Affiliations

    • HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
    • Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD
    • Pediatric Adolescent and Maternal AIDS Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD.
    • Corresponding Author InformationReprint requests: Rohan Hazra, MD, Pediatric Adolescent and Maternal AIDS Branch, National Institute of Child Health and Human Development, 6100 Executive Boulevard, Room 4B11, Bethesda, MD 20892-7510.

Received 18 July 2007 ,Revised 19 October 2007 ,Accepted 11 December 2007.

References 

  1. Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118:e711–e718
  2. Hazra R, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, et al. Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 2004;48:124–129
  3. Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics. 2005;116:e846–e854
  4. Bachrach LK, Hastie T, Wang MC, Narasimhan B, Marcus R. Bone mineral acquisition in healthy Asian, Hispanic, black, and Caucasian youth: a longitudinal study. J Clin Endocrinol Metab. 1999;84:4702–4712
  5. Faulkner RA, Bailey DA, Drinkwater DT, McKay HA, Arnold C, Wilkinson AA. Bone densitometry in Canadian children 8-17 years of Age. Calcif Tissue Int. 1996;59:344–351
  6. Hogg RJ, Furth S, Lemley KV, Portman R, Schwartz GJ, Coresh J, et al. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics. 2003;111:1416–1421
  7. Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Vigano A. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J Acquir Immune Defic Syndr. 2005;40:448–450

 Supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research.

PII: S0022-3476(07)01166-3

doi: 10.1016/j.jpeds.2007.12.020

The Journal of Pediatrics
Volume 152, Issue 4 , Pages 582-584 , April 2008

Article Tools

* Image Usage & Resolution